Dieter F. Braus
Research Subjects
Research Interests
Dieter F. Braus has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- André Tadić
Department of Psychiatry and Psychotherapy, University Medical Centre Mainz, Germany
1 shared publication - Anna K. Berkefeld
Dr. Horst Schmidt Klinik
1 shared publication - Christoph Hiemke
Universitätsmedizin Mainz
1 shared publication - Daniel Wachtlin
Interdisciplinary Centre for Clinical Trials Mainz (IZKS Mainz), University Medical Centre, Johannes Gutenberg University, Mainz, Germany.
1 shared publication - Dietrich van Calker
University of Freiburg
1 shared publication - Joachim Röschke
St Valentinushaus, Clinic for Psychiatry and Psychotherapy, Bad Soden, Germany
1 shared publication
Latest Publications
- 1 January 2011
- Published by Springer Nature
- p. 101-117
2.7 Neurobiological correlates of social exclusion and social pain
- 1 January 2011
- Published by Springer Nature
- p. 101-117
2.7 Neurobiological correlates of social exclusion and social pain
- Open Access
- 26 February 2010
- Published by Springer Nature in Trials
- Vol. 11 (1) , 21
Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial
In Major Depressive Disorder (MDD), the traditional belief of a delayed onset of antidepressants' effects has lead to the concept of current guidelines that treatment durations should be between 3-8 weeks before medication change in case of insufficient outcome. Post hoc analyses of clinical trials, however, have shown that improvement usually occurs within the first 10-14 days of treatment and that such early improvement (Hamilton Depression Rating Scale [HAMD] decrease ≥20%) has a substantial predictive value for final treatment outcome. Even more important, non-improvement (HAMD decrease <20%) after 14 days of treatment was found to be highly predictive for a poor final treatment outcome.
- 26 February 2010
- Published by Springer Nature in Trials
- Vol. 11 (1) , 21
Open AccessRationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial
In Major Depressive Disorder (MDD), the traditional belief of a delayed onset of antidepressants' effects has lead to the concept of current guidelines that treatment durations should be between 3-8 weeks before medication change in case of insufficient outcome. Post hoc analyses of clinical trials, however, have shown that improvement usually occurs within the first 10-14 days of treatment and that such early improvement (Hamilton Depression Rating Scale [HAMD] decrease ≥20%) has a substantial predictive value for final treatment outcome. Even more important, non-improvement (HAMD decrease <20%) after 14 days of treatment was found to be highly predictive for a poor final treatment outcome.